Laser May Be Safer Than Bevacizumab in Babies With Acute-Phase ROP

Source: Medscape

Babies with acute-phase retinopathy of prematurity (ROP) who are treated with bevacizumab have more long-term eye problems than babies treated with laser, according to a new randomized controlled trial done in Italy, as reported in Medscape.

"Our paper demonstrates long-term ocular effects from using an anti-VEGF (anti-vascular endothelial growth factor) drug such as bevacizumab for the treatment of acute-phase ROP. These effects, including abnormalities of the posterior pole and peripheral retina, are seen much more frequently than they are in laser-treated eyes," said coauthor Dr. Graham E. Quinn of the University of Pennsylvania Perelman School of Medicine, in Philadelphia.

Read the full article here.

Related Content